Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Most relevant
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ASTELLAS PHARMA INC.
2018Amgen Astellas Biopharma K.K. and Astellas Pharma Inc. Announce Launch of Rep..
CI
2018ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
PU
2018Astellas Pharma Inc. and Kotobuki Pharmaceutical Co., Ltd. Submit Supplementa..
CI
2018ASTELLAS PHARMA : Application for Marketing Approval Submitted for Bispecific CD..
PU
2017ASTELLAS PHARMA : to Present at J.P. Morgan Healthcare Conference (pdf 178KB)
PU
2017Astellas Appoints Anthony Fiordaliso to Vice President, Americas Finance
CI
2017ASTELLAS PHARMA : Announces First Clinical Data from Phase I Study of Gilteritin..
PU
2017Astellas Announces First Clinical Data from Phase I Study of Gilteritinib in ..
CI
2017ASTELLAS PHARMA : the Institute of Medical Science of the University of Tokyo, C..
PU
2017ASTELLAS PHARMA : Announces Personnel Change(pdf 155KB)
PU
2017ASTELLAS PHARMA : Acquires Mitobridge Under Existing Collaboration(pdf 359KB)
PU
2017ASTELLAS PHARMA : Submits a New Drug Application for Gonax« 12-Week Extended-Rel..
PU
2017Astellas Pharma Inc. Submits a New Drug Application for Gonax 12-Week Extende..
CI
2017Astellas Pharma Inc. exercised its option to acquire remaining 73.6% stake in..
CI
2017ASTELLAS PHARMA : to Present New Data Exploring Gilteritinib in Newly Diagnosed ..
PU
2017ASTELLAS PHARMA : MSD and Astellas conclude co-promotion agreement in Japan for ..
PU
2017ASTELLAS PHARMA : and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Ved..
PU
2017Astellas Announces Leadership Changes in U.S. Health Systems Commercial Organ..
CI
2017ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares (pdf 121KB)
PU
2017Tranche Update on Astellas Pharma Inc.'s Equity Buyback Plan announced on Jul..
CI
2017Astellas Pharma Inc.'s Equity Buyback announced on July 28, 2017 has expired ..
CI
2017ASTELLAS PHARMA : Reports First Half FY2017 Financial Results, Revises Fiscal Ye..
BU
2017Astellas Pharma Inc. Announces Consolidated Earnings Results for the Six Mont..
CI
2017ASTELLAS PHARMA : Positive Topline Results from First Japan Phase 3 Trial for Ro..
PU
2017ASTELLAS PHARMA : Reports First Half FY2017 Financial Results, Revises Fiscal Ye..
PU
2017Astellas Pharma Inc. and FibroGen, Inc. Announces Positive Topline Results fr..
CI
2017ASTELLAS PHARMA : Partners with CNBC for its Global Branding Campaign (pdf 409KB..
PU
2017ASTELLAS PHARMA : Enters into a Screening Collaboration Agreement with MMV to Di..
PU
2017ASTELLAS PHARMA : Extension of Agreement Pertaining to Sale of Telmisartan (Mica..
PU
2017ASTELLAS PHARMA : and Universal Cells, Inc. Announce a Collaboration Utilizing U..
PU
2017ASTELLAS PHARMA : Enters into a New Collaborative Research Agreement with TB All..
PU
2017ASTELLAS PHARMA : U.S. FDA Grants Fast Track Designation to Astellas for Develop..
PU
2017ASTELLAS PHARMA : and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedo..
PU
2017ASTELLAS PHARMA : Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct "JOINUS,"..
PU
2017U.S. FDA Grants Fast Track Designation to Astellas Pharma Inc. for Developmen..
CI
2017ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 311KB)
PU
2017ASTELLAS PHARMA : and TOA EIYO Announce Co-promotion Agreement for Kiklin« Capsu..
PU
2017Tranche Update on Astellas Pharma Inc.'s Equity Buyback Plan announced on Jul..
CI
2017ASTELLAS PHARMA INC : Ex-dividend day for interim dividend
FA
2017ASTELLAS PHARMA : U.S. FDA Accepts for Review Astellas' Supplemental New Drug Ap..
PU
2017U.S. FDA Accepts for Review Astellas Pharma Inc.'s Supplemental New Drug Appl..
CI
2017ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
PU
2017Astellas Pharma Inc Submits Supplemental New Drug Application for Approval of..
CI
2017ASTELLAS PHARMA : Astella Announces Status of Acquisition of Own Shares (pdf 311..
PU
2017ASTELLAS PHARMA : Repatha@ Receives Approval for New 420mg Single-Dose Delivery ..
PU
2017ASTELLAS PHARMA : Announces Personnel Changes and Organizational Changes(..
PU
2017ASTELLAS PHARMA : First Patient Dosed in Phase 3 MORPHO Trial Evaluating Gilteri..
PU
2017Astellas Pharma Inc Announces First Patient Dosed in Phase 3 Morpho Trial Eva..
CI
2017ASTELLAS PHARMA : LTL Pharma Succeeds Marketing Approval for "Nivadil« Tablets",..
PU
2017ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares (pdf 329KB)
PU
2017Astellas Pharma Inc. Submits Marketing Approval Application for Infectious En..
CI
2017Astellas Pharma Inc. authorizes a Buyback Plan.
CI
2017ASTELLAS PHARMA : Announces Acquisition of Own Shares (pdf 310KB)
PU
2017ASTELLAS PHARMA : Reports First Quarter FY2017 Financial Results (pdf 434KB)
PU
2017ASTELLAS PHARMA : Reports First Quarter FY2017 Financial Results
BU
2017Astellas Pharma Inc. Reports Consolidated Earnings Results for the First Quar..
CI
2017Astellas Pharma Inc. announces an Equity Buyback for 50,000,000 shares, repre..
CI
2017Astellas Pharma Inc. Reports Audited Consolidated and Company Earnings Result..
CI
2017ASTELLAS PHARMA : U.S. FDA Grants Orphan-Drug Designation to Astellas for Develo..
PU
2017U.S. FDA Grants Orphan-Drug Designation to Astellas Pharma Inc. for Developme..
CI
2017ASTELLAS PHARMA : Supports the Northern Kyushu Heavy Rain Relief Efforts
PU
2017ASTELLAS PHARMA : Presentation material for Press Conference on July 11th (1.76 ..
PU
2017ASTELLAS PHARMA : Maruho Succeeds Marketing Approval for Anti-Atopic Dermatitis ..
PU
2017ASTELLAS PHARMA : Named to FTSE4Good Sustainability Index for the Sixth Consecut..
PU
2017Astellas Pharma Inc. Submits Supplemental New Drug Application to the U.S. Fo..
CI
2017ASTELLAS PHARMA : The Astellas Oncology C3 Prize Competition Returns for a Secon..
PU
2017ASTELLAS PHARMA : and Pfizer Announce Amendment to Clinical Research Protocol fo..
PU
2017Astellas Pharma Inc. and Pfizer Inc. Announce Amendment to Clinical Research ..
CI
2017ASTELLAS PHARMA : Kyoto University and Astellas Inaugurate "Alliance Station" wi..
PU
2017ASTELLAS PHARMA : Announces Commitments to GHIT Fund Replenishment
PU
2017Astellas Pharma Inc. Proposes Annual Dividend for the Year 2017, Payable on J..
CI
2017ASTELLAS PHARMA : MSD submits application for approval of type-2 diabetes drug c..
PU
2017Astellas Pharma Inc. Announces Oncology Portfolio Updates; Plans to Discontin..
CI
2017Astellas Appoints Mark Schwitzenberg as Vice President of Marketing, Urology ..
CI
2017Astellas Pharma Inc. completed the acquisition of Ogeda SA from Vesalius Bioc..
CI
Prev.2  3  4  5  6   7  8  9  10  11Next
Upcoming event on ASTELLAS PHARMA INC.